Larka is pleased to announce it performed the Commercial Due Diligence for Partners Group—supporting its acquisition of FairJourney Biologics, a leading antibody discovery Contract Research Organization (CRO).
Partners Group, one of the largest firms in the global private markets industry, acting on behalf of its clients, has agreed to acquire a majority stake in FairJourney Biologics, a leading Contract Research Organization (CRO) supporting biotech and pharma companies in the development of antibody-based therapies.
While already established as a leader in antibody discovery and development, Partners Group’s acquisition—alongside a minority reinvestment from GHO Capital Partners, the company’s owner since 2020—will enable FairJourney to further expand its technologies and service offering globally.
RELATED PRACTICE
Mergers & Acquisitions
How we supported Partners Group
Acting as the Buy-Side Commercial Due Diligence advisor, Larka provided Partners Group with key insights and recommendations, aiding in the acquisition of FairJourney Biologics by the firm.
“We are proud to have supported Partners Group in the success of this significant transaction. With the great deal of talent and industry experience within Partners Group teams, we are confident that FairJourney is well on its way to becoming a world-leading antibody drug discovery CRO.”
Pierre-Anthony Brioir – Senior Director at Larka
This Commercial Due Diligence process leveraged our M&A practice’s extensive biopharmaceutical industry knowledge—in this case the antibody drug discovery market—to provide Partners Group with a comprehensive picture of FairJourney’s:
- Core value proposition within the antibody drug discovery market
- Antibody drug discovery market dynamics and market sizing
- Competitive environment
- Customer environment & market feedbacks
- Growth avenues
- Operational risk assessment
Interested in our M&A capabilities?
About Larka: the buy-side commercial due diligence provider
Larka is a management consulting firm exclusively dedicated to the Pharma & Biotech industry. For over 30 years, we have been assisting any organizations somehow involved technically, commercially or financially into drug discovery, development, manufacturing or testing. Our clients include Biotech & Pharma companies, Contract or Central Services Providers, Analytical Labs, Equipment, Raw Materials or Ingredients Suppliers, Private Equity firms or Investment Banks, Public Institutions or Non-Governmental Organizations.
Addressing all of the Technical, Operational, Commercial and Strategic challenges faced by Bio-Pharma industry businesses, we bring an unparalleled 360° expertise to our clients—providing them with a clear appreciation of their capabilities and a full-potential vision of the market's opportunities, synergies and risks.